

Module 2.5: Clinical Overview

Bimatoprost/timolol preservative free, eye drops solution in multidose container by Pharmathen

Pharmacist
Senior Clinical & Biopharmaceutical Expert
Specialised in Clinical Toxicology
Pharmathen S.A, Athens, Greece

Table of Contents

2.5 Clinical Overview	3
2.5.1 Overview of the Clinical Testing Strategy	3
2.5.2. Product Development Rationale	4
2.5.3. Overview of Biopharmaceutics	5
2.5.3.1. Biowaiver	6
2.5.4. Overview of Clinical Pharmacology	9
2.5.4.1. Overview of Human Pharmacodynamics	10
2.5.4.2. Overview of Clinical Pharmacokinetics	17
Absorption.....	17
Distribution.....	18
Metabolism.....	19
Elimination.....	20
2.5.5. Overview of Efficacy	24
2.5.5.1 Clinical studies of bimatoprost	26
2.5.5.2 Bimatoprost comparison to other drugs used for the same indication	28
2.5.5.3 Dose-ranging studies with timolol	29
2.5.5.4 Timolol clinical studies and comparative studies	30
2.5.5.5 Combination therapy	36
2.5.5.6. Use in Children	36
2.5.6. Overview of Safety	39
2.5.6.1. Clinical Safety	39
2.5.6.2 Undesirable effects	45
2.5.6.3 Pregnancy and Lactation	47
2.5.6.4 Drug Interactions	49
2.5.7. Benefits and Risks Conclusions	51
2.5.8. List of Literature References	52

2.5 Clinical Overview

2.5.2. Product Development Rationale

2.5.3. Overview of Biopharmaceutics

2.5.4. Overview of Clinical Pharmacology

2.5.4.1. Overview of Human Pharmacodynamics

2.5.4.2. Overview of Clinical Pharmacokinetics

2.5.5. Overview of Efficacy

2.5.5.1 Clinical studies of bimatoprost

2.5.6. Overview of Safety

2.5.8. List of Literature References

Aasved H, Seland JH, Slagsvold JE (1979): Timolol maleate in treatment of open angle glaucoma; *Acta Ophthalmol (Copenh)*, 57, 700-8.

AHFS drug information 2008. McEvoy GK, ed. Timolol. Bethesda, MD: American Society of Health-System Pharmacists, 2008:2930-2932.

Berry DP Jr, Van Buskirk EM, Shields MB (1984): Betaxolol and timolol. A comparison of efficacy and side effects; *Arch Ophthalmol*, 102, 42-5.

Boger WP 3rd, Puliafito CA, Steinert RF, Langston DP (1978): Long-term experience with timolol ophthalmic solution in patients with open-angle glaucoma; *Ophthalmology*, 85, 259-67.

Boger WP 3rd, Walton DS (1981): Timolol in uncontrolled childhood glaucomas; *Ophthalmology*, 88, 253-8.

Brazier DJ, Smith SE (1988): Ocular and cardiovascular response to topical carteolol 2% and timolol 0.5% in healthy volunteers, *Br J Ophthalmol*, 72, 101-3.

Camras CB (1996): Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group, *Ophthalmology*, 103, 138-47.

Cantor LB. Clinical pharmacology of bimatoprost. *Expert Opin Drug Metab Toxicol*. 2005 Jun;1(1):151-7.

Cantor LB, Hoop J, Morgan L, Wudunn D, Catoira Y; Bimatoprost-Travoprost Study Group. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. *Br J Ophthalmol*. 2006 Nov;90(11):1370-3.

Chabi A, Varma R, Tsai JC, Lupinacci R, Pigeon J, Baranak C, Noble L, Lines C, Ho TW. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension. *Am J Ophthalmol*. 2012 Jun;153(6):1187-96.

Cheng JW, Cheng SW, Gao LD, Lu GC, Wei RL. Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. *PLoS One*. 2012;7(9):e45079.

Coakes RL, Brubaker RF (1978): The mechanism of timolol in lowering intraocular pressure. In the normal eye; *Arch Ophthalmol*, 96, 2045-8.

Costagliola C, Campa C, Parmeggiani F, Incorvaia C, Perri P, D'Angelo S, Lamberti G, Sebastiani A (2007): Effect of 2% dorzolamide on retinal blood flow: a study on

juvenile primary open-angle glaucoma patients already receiving 0.5% timolol, *Br J Clin Pharmacol*, 63, 376-9.

Day DG, Walters TR, Schwartz GF, Mundorf TK, Liu C, Schiffman RM, Bejanian M. Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. *Br J Ophthalmol*. 2013 Aug;97(8):989-93.

de Jong C, Stolwijk T, Kuppens E, de Keizer R, van Best J (1994): Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma; *Graefes Arch Clin Exp Ophthalmol*, 232, 221-4.

Demailly P, Lehner MA, Etienne R, Trepsat C, Haut J, Raynaud G, Massin M, Tetry C (1978): Results of a double-blind medium-term study comparing effects of timolol maleate and epinephrine in 120 patients with chronic open-angle glaucoma; *J Fr Ophtalmol*, 1, 727-32.

Distellhorst JS, Hughes GM (2003): Open-angle glaucoma; *Am Fam Physician*, 67, 1937-1944.

Figus M, Nardi M, Piaggi P, Sartini M, Guidi G, Martini L, Lazzeri S. Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients. *Eye (Lond)*. 2014 Apr;28(4):422-9.

Fourtillan JB, Courtois P, Lefebvre MA, Girault J (1981): Pharmacokinetics of oral timolol studied by mass fragmentography; *Eur J Clin Pharmacol*, 19, 193-6.

Fuchsjäger-Mayrl G, Georgopoulos M, Hommer A, Weigert G, Pemp B, Vass C, Garhöfer G, Schmetterer L. Effect of dorzolamide and timolol on ocular pressure: blood flow relationship in patients with primary open-angle glaucoma and ocular hypertension. *Invest Ophthalmol Vis Sci*. 2010 Mar;51(3):1289-96.

Fuchsjäger-Mayrl G, Wally B, Rainer G et al (2005): Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension; *Br J Ophthalmol*, 89, 1293-1297.

Furrer P, Berger J, Mayer JM, Gurny R (2001): A comparative study of the ocular tolerance of 3 timolol-based preparations: the influence of preservatives on ocular tolerance; *J Fr Ophtalmol*, 24, 13-19.

Ganfort eye drops, solution; (EMA Summary of Product Characteristics; Procedure No. EMA/H/C/000668); 10 March 2016. Available at:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000668/WC500020625.pdf

Ganfort eye drops, solution; (EMA Scientific Discussion; Procedure No. EMA/H/C/000668); 19 May 2006. Available at:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000668/WC500020622.pdf

Gupta D (2005): Current concepts in the medical management of glaucoma; *Contemp Optom*, 3, 1-8.

Heijl A, Strahlman E, Sverrisson T et al (1997): A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension; *Ophthalmology*, 104, 137-142.

Hoskins HD Jr, Hetherington J Jr, Magee SD, Naykhin R, Migliazzo CV (1985): Clinical experience with timolol in childhood glaucoma; *Arch Ophthalmol*, 103, 1163-5.

Hoyng PFJ, van Beek LM (2000): Pharmacological therapy for glaucoma; *Drugs*, 59, 411-434.

Ichhpujani P, Katz LJ, Hollo G, Shields CL, Shields JA, Marr B, Eagle R, Alvim H, Wizov SS, Acheampong A, Chen J, Wheeler LA. Comparison of human ocular distribution of bimatoprost and latanoprost. *J Ocul Pharmacol Ther*. 2012 Apr;28(2):134-45.

Inan UU, Ermis SS, Orman A, Onrat E, Yucel A, Ozturk F, Asagidag A, Celik A. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. *J Ocul Pharmacol Ther*. 2004 Aug;20(4):293-310.

Ishizaki T, Tawara K, Oyama Y, Nakaya H (1978): Clinical pharmacologic observations on timolol. I. Disposition and effect in relation to plasma level in normal individuals; *J Clin Pharmacol*, 18, 511-8.

Kaila T, Salminen L, Huupponen R (1985): Systemic absorption of topically applied ocular timolol; *J Ocul Pharmacol*, 1, 79-83.

Kammer JA, Katzman B, Ackerman SL, Hollander DA. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study. *Br J Ophthalmol*. 2010 Jan;94(1):74-9.

Kanner E, Tsai JC (2006): Glaucoma medications: use and safety in the elderly population; *Drugs Aging*, 23, 321-332.

Katz IM, Hubbard WA, Getson AJ, Gould AL (1976): Intraocular pressure decrease in normal volunteers following timolol ophthalmic solution; *Invest Ophthalmol*, 15, 489-92.

Katz LJ (1999): Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group; Am J Ophthalmol, 127, 20-6.

Katz LJ, Cohen JS, Batoosingh AL, Felix C, Shu V, Schiffman RM. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol. 2010 Apr;149(4):661-671.

Keates EU, Stone R (1984): The effect of d-timolol on intraocular pressure in patients with ocular hypertension; Am J Ophthalmol, 98, 73-8.

Kendall K, Mundorf T, Nardin G, Zimmerman TJ, Hesse R, Lavin P (1987): Tolerability of timolol and betaxolol in patients with chronic open-angle glaucoma; Clin Ther, 9, 651-5.

Khaw PT, Shah P, Elkington AR (2004): Glaucoma-2: Treatment; BMJ, 328, 156-158.

Kitazawa Y, Tsuchisaka H (1980): Effects of timolol on corneal sensitivity and tear production; Int Ophthalmol, 3, 25-9.

Konstas AG, Stewart WC, Topouzis F, Tersis I, Holmes KT, Stangos NT (2001): Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma; Am J Ophthalmol, 131, 729-33.

Korte JM, Kaila T, Saari KM (2002): Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops; Graefes Arch Clin: Exp Ophthalmol, 240, 430-5.

Krauss A, Woodward D. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol. 2004 Mar;49 Suppl 1:S5-11.

Lee DA, Higginbotham EJ (2005): Glaucoma and its treatment: a review; AJHP, 62, 691-699.

Li N, Chen XM, Zhou Y, Wei ML, Yao X (2006): Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials; Clin Experiment Ophthalmol, 34, 755-64.

Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.

Lumigan® 0.1 mg/mL eye drops, solution; (EMA Scientific Discussion; Procedure No. EMA/H/C/391/X/0026); 7 January 2010. Available at:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000391/WC500074096.pdf

Lumigan® 0.3 mg/mL eye drops, solution; (EMA Scientific Discussion; Procedure No EMA/H/C/000391); 8 March 2002. Available at:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000391/WC500044432.pdf

Lustgarten JS, Podos SM (1983): Topical timolol and the nursing mother; Arch Ophthalmol, 101, 1381-2.

Madadi P, Koren G, Freeman DJ, Oertel R, Campbell RJ, Trope GE (2008): Timolol concentrations in breast milk of a woman treated for glaucoma: calculation of neonatal exposure; J Glaucoma, 17, 329-31.

Maier PC, Funk J, Schwarzer G et al (2005): Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials; BMJ, 331, 134.

March WF, Ochsner KI (2000): The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group, Am J Ophthalmol, 129, 136-43.

Marén N, Calissendorff BM (1985): Timolol in aqueous humour after topical administration. A pilot study, Acta Ophthalmol (Copenh), 63, 415-7.

Marquis RE, Whitson JT (2005): Management of glaucoma: focus on pharmacological therapy; Drugs Aging, 22, 1-21.

Melamed S, David R (2000): Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II; Clin Ther, 22, 103-11.

Nielsen NV (1978): Timolol. Hypotensive effect, used alone and in combination for treatment of increased intraocular pressure; Acta Ophthalmol (Copenh), 56, 504-9.

Nieminen T, Lehtimäki T, Mäenpää J, Ropo A, Uusitalo H, Kähönen M (2007): Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects; Scand J Clin Lab Invest, 67, 237-45.

Niiya A, Yokoi N, Matsumoto Y, Komuro A, Ishibashi T, Tomii S, He J, Kinoshita S (2000): Effect of beta-blocker eyedrops on corneal epithelial barrier function; Ophthalmologica, 214, 332-6.

Nixon DR. A randomized, prospective study of bimatoprost 0.01% or travoprost/timolol in patients previously treated with latanoprost and timolol to reduce intraocular pressure. J Ocul Pharmacol Ther. 2013 Dec;29(10):876-81.

Novack GD, O'Donnell MJ, Molloy DW (2002): New glaucoma medications in the geriatric population: efficacy and safety; JAGS, 50, 956-962.

Ober M, Scharrer A, David R, Biedner BZ, Novack GD, Lue JC, Robins DS, Duzman E (1985): Long-term ocular hypotensive effect of levobunolol: results of a one-year study; *Br J Ophthalmol*, 69, 593-9.

Ostergaard Laursen S, Bjerrum P (1982): Timolol eyedrop-induced severe bronchospasm; *Acta Med Scand*, 211, 505-6.

Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. *Am J Ophthalmol*. 2003 May;135(5):688-703.

Phillips CI, Bartholomew RS, Levy AM, Grove J, Vogel R (1985): Penetration of timolol eye drops into human aqueous humour: the first hour; *Br J Ophthalmol*, 69, 217-8.

Putterman GJ, Davidson J, Albert J (1985): Lack of metabolism of timolol by ocular tissues, *J Ocul Pharmacol*, 1, 287-96.

Quaranta L, Katsanos A, Floriani I, Riva I, Russo A, Konstas AG. Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma. *J Clin Pharmacol*. 2012 Oct;52(10):1552-7.

Saari KM, Ali-Melkkilä T, Vuori ML, Kaila T, Iisalo E (1993): Absorption of ocular timolol: drug concentrations and beta-receptor binding activity in the aqueous humour of the treated and contralateral eye; *Acta Ophthalmol (Copenh)*, 71, 671-6.

Sato S, Hirooka K, Baba T, Mizote M, Fujimura T, Tenkumo K, Ueda H, Shiraga F. Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma. *J Ocul Pharmacol Ther*. 2011 Oct;27(5):499-502.

Schwartz K, Budenz D. Current management of glaucoma. *Curr Opin Ophthalmol*. 2004 Apr;15(2):119-26.

Sharir M, Zimmerman TJ, Crandall AS, Mamalis N (1993): A comparison of the ocular tolerability of a single dose of timolol and levobunolol in healthy normotensive volunteers; *Ann Ophthalmol*, 25, 133-7.

Siesky B, Harris A, Sines D, Rechtman E, Malinovsky VE, McCranor L, Yung CW, Zalish M (2006): A comparative analysis of the effects of the fixed combination of timolol and dorzolamide versus latanoprost plus timolol on ocular hemodynamics and visual function in patients with primary open-angle glaucoma; *J Ocul Pharmacol Ther*, 22, 353-61.

Silverstone D, Zimmerman T, Choplin N, Mundorf T, Rose A, Stoecker J, Kelley E, Lue J (1991): Evaluation of once-daily levobunolol 0.25% and timolol 0.25% therapy for increased intraocular pressure; *Am J Ophthalmol*, 15, 56-60.

Sonntag JR, Brindley GO, Shields MB (1978): Effect of timolol therapy on outflow facility; Invest Ophthalmol Vis Sci, 17, 293-6.

Stamer WD, Piwnica D, Jolas T, Carling RW, Cornell CL, Fliri H, Martos J, Pettit SN, Wang JW, Woodward DF. Cellular basis for bimatoprost effects on human conventional outflow. Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5176-81.

Stewart RH, Kimbrough RL, Ward RL (1986): Betaxolol vs timolol. A six-month double-blind comparison; Arch Ophthalmol, 104, 46-8.

Stewart WC, Day DG, Sharpe ED, Dubiner HB, Holmes KT, Stewart JA (1999): Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost; Am J Ophthalmol, 128, 692-6.

Takki KK, Klemetti A, Valle O (1982): The IOP-lowering effect of timolol in simple and capsular glaucoma. A multicenter study in Finland; Graefes Arch Clin Exp Ophthalmol, 218, 83-7.

Tang-Liu D, Cherukury M, Acheampong A, Cheetham J, VanDenburgh A and Yu D. Systemic Pharmacokinetics of Bimatoprost 0.03% Solution Following Once Daily Ocular Dosing In Normal, Healthy Subjects. Invest Ophthalmol Vis Sci 2002;43: E-Abstract 1085.

Tung JD, Tafreshi A, Weinreb RN, Slight JR, Medeiros FA, Liu JH. Twenty-four-hour effects of bimatoprost 0.01% monotherapy on intraocular pressure and ocular perfusion pressure. BMJ Open. 2012 Aug 23;2(4).

Umetsuki MH, Kotegawa T, Nakamura K, Nakano S, Nakatsuka K (1997): Temporal variation in the effects of ophthalmic timolol on cardiovascular and respiratory functions in healthy men; J Clin Pharmacol, 37, 58-63.

van der Valk R, Webers CA, Schouten JS et al (2005): Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials; Ophthalmology, 112, 1177-1185.

Wan Z, Woodward DF, Cornell CL, Fliri HG, Martos JL, Pettit SN, Wang JW, Kharlamb AB, Wheeler LA, Garst ME, Landsverk KJ, Struble CS, Stamer WD. Bimatoprost, prostamide activity, and conventional drainage. Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4107-15.

Wang K, Xu L, Yuan Z, Yao K, Zhao J, Xu L, Fang A, Zhang M, Wu L, Ji J, Hou J, Liu Q, Sun X. Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China. BMC Ophthalmol. 2014 Feb 25;14:21.

Weinreb RN, Khaw PT (2004): Primary open-angle glaucoma; Lancet, 363, 1711-1720.

West DR, Lischwe TD, Thompson VM, Ide CH (1988): Comparative efficacy of the beta-blockers for the prevention of increased intraocular pressure after cataract extraction; *Am J Ophthalmol*, 106, 168-73.

Williams RD, Cohen JS, Gross RL, Liu CC, Safyan E, Batoosingh AL; Bimatoprost Study Group. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. *Br J Ophthalmol*. 2008 Oct;92(10):1387-92.

Woodward D, Krauss A, Chen J, Lai R, Spada C, Burk R, Andrews S, Shi L, Liang Y, Kedzie K, Chen R, Gil D, Kharlamb A, Archeampong A, Ling J, Madhu C, Ni J, Rix P, Usansky J, Usansky H, Weber A, Welty D, Yang W, Tang-Liu D, Garst M, Brar B, Wheeler L, Kaplan L. The pharmacology of bimatoprost (Lumigan). *Surv Ophthalmol*. 2001 May;45 Suppl 4:S337-45.

Woodward DF, Wang JW, Poloso NJ. Recent progress in prostaglandin F_{2α} ethanolamide (prostanoid F_{2α}) research and therapeutics. *Pharmacol Rev*. 2013 Jul 26;65(4):1135-47.

Wu PY, Riegel M, Ellis PP (1989): High-performance liquid chromatographic assay for timolol in the aqueous humor of the eye; *J Chromatogr*, 29, 368-75.

Zimmerman TJ, Harbin R, Pett M, Kaufman HE (1977a): Timolol and facility of outflow; *Invest Ophthalmol Vis Sci*, 16, 623-4.

Zimmerman TJ, Kass MA, Yablonski ME, Becker B (1979): Timolol maleate: efficacy and safety; *Arch Ophthalmol*, 97, 656-8.

Zimmerman TJ, Kaufman HE (1977b): Timolol, dose response and duration of action; *Arch Ophthalmol*, 95, 605-7.

Zimmerman TJ, Kooner KS, Morgan KS (1983): Safety and efficacy of timolol in pediatric glaucoma; *Surv Ophthalmol*, 28, 262-4.